These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28836356)

  • 21. Targeted drug development for arthritis.
    Malemud CJ
    Future Med Chem; 2012 Apr; 4(6):701-3. PubMed ID: 22530633
    [No Abstract]   [Full Text] [Related]  

  • 22. GM-CSF as a therapeutic target in inflammatory diseases.
    van Nieuwenhuijze A; Koenders M; Roeleveld D; Sleeman MA; van den Berg W; Wicks IP
    Mol Immunol; 2013 Dec; 56(4):675-82. PubMed ID: 23933508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.
    Di Franco M; Gerardi MC; Lucchino B; Conti F
    Core Evid; 2014; 9():41-8. PubMed ID: 24648832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of rheumatoid arthritis: Unraveling the conundrum.
    Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
    J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.
    Municio C; Dominguez-Soto Á; Fuentelsaz-Romero S; Lamana A; Montes N; Cuevas VD; Campos RG; Pablos JL; González-Álvaro I; Puig-Kröger A
    Ann Rheum Dis; 2018 May; 77(5):752-759. PubMed ID: 29431121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
    Frey N; Grange S; Woodworth T
    J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are we seeing a resurgence in the use of natural products for new drug discovery?
    Li F; Wang Y; Li D; Chen Y; Dou QP
    Expert Opin Drug Discov; 2019 May; 14(5):417-420. PubMed ID: 30810395
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
    Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
    [No Abstract]   [Full Text] [Related]  

  • 32. Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery.
    Yarwood A; Eyre S; Worthington J
    Expert Opin Drug Discov; 2016 Aug; 11(8):805-13. PubMed ID: 27267163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.
    Tanaka Y; Takeuchi T; Umehara H; Nanki T; Yasuda N; Tago F; Kawakubo M; Kitahara Y; Hojo S; Kawano T; Imai T
    Mod Rheumatol; 2018 Jan; 28(1):58-65. PubMed ID: 28681650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Putting new disease-modifying antirheumatic drugs into perspective.
    Saseen JJ
    Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
    [No Abstract]   [Full Text] [Related]  

  • 36. Future therapeutic targets in rheumatoid arthritis?
    Cheung TT; McInnes IB
    Semin Immunopathol; 2017 Jun; 39(4):487-500. PubMed ID: 28451787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative efficacy of infliximab and adalimumab in patients with rheumatoid arthritis].
    Tiurin VP; Mezenova TV; Iutrina TO; Usacheva IuV
    Klin Med (Mosk); 2013; 91(7):55-60. PubMed ID: 24437172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.
    Hamilton JA
    Expert Rev Clin Immunol; 2015 Apr; 11(4):457-65. PubMed ID: 25748625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
    Glassman PM; Balthasar JP
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.